Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Pratham Investments has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE21-10-2016
21-10-2016
Update on divestment of seven prescription brands of the Company to RPG Life Sciences Ltd - Closure of transaction
With reference to the earlier letter dated July 27, 2016, regarding agreement entered with RPG Life Sciences Ltd to divest seven prescription brands in India, owned by Sun Pharmaceutical Industries Limited and its subsidiary.Further to the above, Sun Pharmaceutical Industries Ltd has now informed BSE that the Company have received the approval of the Competition Commission of India and all the necessary formalities for Closure of the said...21-10-2016
Updates on Completion of Buy back Offer
With reference to the earlier Announcement letter dated October 20, 2016, Sun Pharmaceutical Industries Ltd has informed BSE that copy of the Corrigendum to the Post Buyback Public Announcement dated October 20, 2016 published in newspapers on October 21, 2016, inter alia stating that the numbers of shares mentioned under Post Buyback under heading of Promoter and Persons in Control and other category of shareholders shall be read as "1,319,322,620"...21-10-2016
Completion of Buyback and Submission of Post Buyback Public Announcement.
Sun Pharmaceutical Industries Ltd has submitted to BSE regarding the Completion of Buyback and Submission of Post Buyback Public Announcement.21-10-2016
Shareholding for the Period Ended September 30, 2016
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here20-10-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Sun Pharmaceutical Industries Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.20-10-2016
Sun Pharma and ICGEB to develop novel dengue vaccine
Sun Pharma and ICGEB signed an agreement to develop a vaccine targeted against all four serotypes of dengue virus20-10-2016
Sun Pharma & ICGEB announce new exclusive collaboration to develop novel dengue vaccine for India & Global markets
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated October 19, 2016 titled "Sun Pharma & ICGEB announce new exclusive collaboration to develop novel dengue vaccine for India & Global markets".19-10-2016
Dilip Shanghvi, M&A; artist behind India's best stock, now faces his greatest test
Dilip Shanghvi s deal-making mystique is called into question as Sun Pharmaceuticals faces an array of challenges at home and abroad13-10-2016
Clarification on the strike by some Medical Representatives and the ongoing Court Case
Sun Pharmaceutical Industries Ltd has informed BSE regarding "Clarification on the strike by some Medical Representatives and the ongoing Court Case".12-10-2016